While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial - https://clinicaltrials.gov/ct2/show/NCT04322188?term=SISCO&draw=2&rank=1)  on Siltuximab (Sylvant©). EUSA has published the following Press Release on the subject - https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/ and preliminary results could be found here...

EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19. While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study...

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its current exclusive distribution of Qarziba® via Managed Access Program in Russia/CIS region, to cover additionally the LATAM(1)  and APAC(2) regions. About Qarziba® Qarziba® (Dinutuximab beta) is an anti-GD2 monoclonal antibody...

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce the launch on February 12, 2019. The new site launch is available and the URL is www.farmamondo.com The updated site includes changes to...

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce the launch on February 12, 2019. The new site launch is available and the URL is www.farmamondo.com The updated site includes changes to...

FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. With this license in place, FarmaMondo Nordics provides a complete direct to hospital solution for Nordic region healthcare providers seeking the import and supply of unlicensed medicines through its...

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region. FarmaMondo to manage access to Spectrila® for patients with acute lymphoblastic leukemia in Russia, Georgia, Azerbaijan, Kyrgyzstan, Uzbekistan, Moldova. Spectrila® has been...